Navigation Links
KAHR Medical, a Hadasit Bio-Holdings Portfolio Company, to Raise $2.6 Million
Date:6/18/2012

JERUSALEM, June 18, 2012 /PRNewswire/ -- Hadasit Bio-Holdings ("HBL") (TASE: HDST, OTC: HADSY) a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by the Hadassah University Hospital, Israel's foremost medical research center, today announced that KAHR Medical Ltd. ("KAHR"), a portfolio company in which HBL and Sanofi (NYSE: SNY) hold approximately 70% and 20% respectively, will raise $2.6 million at a pre-investment valuation of $11 million.

Thomas Eldered, co-owner of Recipharm (www.recipharm.com), one of the largest pharmaceutical Contract Development and Manufacturing Organizations (CDMO) in Europe, will invest $2 million and hold approximately 15% of the company. Sanofi, the third largest pharmaceutical company in the world, will maintain its current holdings with an investment of $500,000. HBL will invest an additional $100,000 and reduce its holding in the company to approximately 55%.

Ophir Shahaf, CEO of HBL, commented on the investment round, "This investment is another significant achievement following a string of strategic agreements that we have recently closed in our portfolio companies. Forming synergistic collaborations with our partners is a major part of our strategy, and the pre-investment valuations of our recent deals reflect the recognition of value that global pharmaceutical companies give to our portfolio companies. Additional developments - clinical, scientific and strategic - are in progress and are expected to materialize in the coming months, creating substantial value for our shareholders."

Dr. Noam Shani, CEO of KAHR, stated, "We are proud of this investment agreement. I am convinced that the partnership with Mr. Eldered, co-founder and CEO of one of the leading pharmaceutical CDMOs in Europe, will bring significant benefits to KAHR. Additionally, Sanofi's pro rata investment, maintaining its holdings in KAHR, is a vote of confidence for the company, its management and technology. We are proud of our close relationship with Sanofi and their commitment to KAHR. The Company is now well positioned for success with its innovative cutting edge technology and strategic investors, enabling it to accelerate the development of its two lead products. "

KAHR Medical is developing a technology platform known as SCP (Signal Converter Proteins), which allows the construction of protein-based drugs with two functional sides. In contrast to current biological drugs that possess only one functional side, the two functional sides of SCPs allow these drugs to block or activate two reinforcing biological signals at the same time. The SCP platform forms a new generation of biological drugs with great diversity and superior efficacy.

KAHR's leading products, KAHR-101 and KAHR-102, are in pre-clinical development towards treatment of several cancers and autoimmune diseases and are expected to enter clinical trials next year.

About KAHR Medical:
KAHR develops novel drugs that are based on the SCP (Signal Converter Proteins) platform technology for the treatment of cancer and autoimmune diseases. The company's technology is based on many years of research by Dr. Michal Darnitzki Elhallel, Head of Nephrology and a senior researcher at the Hadassah Medical Center, and Professor Mark Tykocinski, dean of the School of Medicine at Jefferson University in Philadelphia and former Chief of Pathology at the University of Pennsylvania. KAHR Medical is managed by Dr. Noam Shani.

For more information please visit - www.kahr-medical.com

About Hadasit Bio-Holdings:
Hadasit Bio-Holdings, Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel's foremost medical research center. The Company was established for the purpose of promoting and commercializing the intellectual property and R&D capabilities generated by Hadassah.

HADSY is the domestically traded ADR of Hadasit Bio-Holdings, a public investment vehicle of six portfolio biotech companies all based on inventions developed by Hadassah.  Hadasit Bio-Holdings focuses on advancing companies that have already shown proof of concept and successful preclinical trials to completion of Phase I/II.

The portfolio companies develop drugs with blockbuster potential (targeting markets that are worth over a billion dollars) operating in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells - areas in which the Hadassah Hospital has extensive knowledge and recognition as a global leader. The company is managed by Ophir Shahaf.

For more information please visit:  www.hbl.co.il

Contact:
KCSA Strategic Communications
Rob Fink / Josh Dver
212.896.1206 / 1239
rfink@kcsa.com / jdver@kcsa.com


'/>"/>
SOURCE Hadasit Bio-Holdings
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Overall Category in Medical, Dental & Related Services/Trade
2. MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Cover in the Medical, Dental & Related Services/Trade Category
3. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
4. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
5. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
6. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
7. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
8. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
9. Nycomed, a Takeda Company, Launches Omnaris® Nasal Spray in the UAE for the Treatment of Allergic Rhinitis
10. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
11. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , February 12, 2016 ... Efforts by Enabling Scientific Understanding of Complex Diseases ... Rare Diseases --> ... diagnostics in South Asia and a leading provider of ... contribute $10 million to the GenomeAsia 100K consortium ...
(Date:2/11/2016)... 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... 2015. --> --> For ... of $29.3 million, or $0.34 loss per share, compared to a ... the same period in 2014. For the year ended December 31, ... $1.05 loss per share, as compared to a net loss of ...
(Date:2/11/2016)... Germany and GERMANTOWN, Maryland ... QGEN ; Frankfurt Prime Standard: QIA) today announced the ... Panels for gene expression profiling, expanding QIAGEN,s portfolio of ... panels enable researchers to select from over 20,000 human ... discover interactions between genes, cellular phenotypes and disease processes. ...
(Date:2/11/2016)... Feb. 11, 2016  Spectra BioPharma Selling Solutions (Spectra) ... provides biopharma companies the experience, expertise, operational delivery ... outsourced sales teams. Created in concert with industry ... the strategic and tactical needs of its clients ... through both personal and non-personal promotion. ...
Breaking Biology Technology:
(Date:1/20/2016)... 20, 2016 A market that just keeps ... from the explosion in genomics knowledge. Learn all about ... A range of dynamic trends are pushing market growth ... medicine - pharmacogenomics - pathogen evolution - next generation ... - greater understanding of the role of genetic material ...
(Date:1/15/2016)... Rico , Jan. 15, 2016 Recent ... and small to find new ways to ensure data ... iOS and Android that ... on biometrics, transforming it into a hardware authorization token. ... users swipe their fingerprint on their KodeKey enabled device ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the leading ... 10,000 retail locations, web and mobile, today announced ... million from existing investors. --> ... devoted to further innovate higi,s health platform – ... web portal – including expanding services and programs ...
Breaking Biology News(10 mins):